Sickle cell drug candidate tested in first human trial – but study halted early

NCT ID NCT05660265

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a first-in-human study testing a single dose of an experimental drug called GSK4172239D in 11 people with sickle cell disease. The main goals were to check safety and how the drug moves through the body. The study was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK4172239D (a prodrug that turns into GSK4106401 in the body)
What this could lead to: If successful, this could point toward a new oral treatment option for sickle cell disease.
What could go wrong: This was a very early (Phase 1) trial with only 11 participants, and it was terminated, so results may not be available or applicable. The drug is still experimental and may not prove safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAEMIA, SICKLE CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAEMIA, SICKLE CELL HEMATOLOGIC DISEASES

Contacts and locations

Locations

GSK Investigational Site

Miami, Florida, 33155, United States
GSK Investigational Site

Tamarac, Florida, 33321, United States
GSK Investigational Site

Atlanta, Georgia, 30315, United States
GSK Investigational Site

Columbus, Georgia, 31904, United States
GSK Investigational Site

Riverdale, Georgia, 30274, United States
GSK Investigational Site

Las Vegas, Nevada, 89113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.